Last reviewed · How we verify
Tham (trometamol)
Tham (generic name: trometamol) is a trometamol drug developed by Pfizer. It is currently FDA-approved (first approved 1965) for Allergic conjunctivitis, Post-Op Ocular Inflammation, Post-Op Photophobia.
At a glance
| Generic name | trometamol |
|---|---|
| Sponsor | Pfizer |
| Drug class | trometamol |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
| First approval | 1965 |
Approved indications
- Allergic conjunctivitis
- Post-Op Ocular Inflammation
- Post-Op Photophobia
- Postoperative Ocular Pain
Common side effects
- Respiratory depression
- Hepatocellular necrosis
- Venous thrombosis or phlebitis
- Hypervolemia
- Local tissue damage and subsequent sloughing
- Chemical phlebitis
- Venospasm
- Infection at the site of injection
- Febrile response
Key clinical trials
- A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial) (PHASE2)
- The Efficiency of Periarticular Multimodal Drug Injection in Pain Management Following Primary Unilateral TKA (NA)
- Nonopioid Analgesia After Anterior Cruciate Ligament Reconstruction (PHASE2,PHASE3)
- Ear Pressure Points Plus Pain Meds for Faster Kidney Stone Pain Relief (NA)
- Low-Dose Short-Term Ketorolac to Reduce Chronic Opioid Use in Orthopaedic Polytrauma Patients (PHASE4)
- NSAID Injection Versus Corticosteroid Injection for Basilar Thumb Arthritis (PHASE3)
- A Study of Tris-Hydroxymethyl Aminomethane (THAM) Versus Sodium Bicarbonate in Cardiac Surgical Patients (PHASE4)
- Ketorolac Intravenous Regional Analgesia in Lower Limb Surgeries (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tham CI brief — competitive landscape report
- Tham updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about Tham
What is Tham?
Tham (trometamol) is a trometamol drug developed by Pfizer, indicated for Allergic conjunctivitis, Post-Op Ocular Inflammation, Post-Op Photophobia.
What is Tham used for?
Tham is indicated for Allergic conjunctivitis, Post-Op Ocular Inflammation, Post-Op Photophobia, Postoperative Ocular Pain.
Who makes Tham?
Tham is developed and marketed by Pfizer (see full Pfizer pipeline at /company/pfizer).
What is the generic name of Tham?
trometamol is the generic (nonproprietary) name of Tham.
What drug class is Tham in?
Tham belongs to the trometamol class. See all trometamol drugs at /class/trometamol.
When was Tham approved?
Tham was first approved on 1965.
What development phase is Tham in?
Tham is FDA-approved (marketed).
What are the side effects of Tham?
Common side effects of Tham include Respiratory depression, Hepatocellular necrosis, Venous thrombosis or phlebitis, Hypervolemia, Local tissue damage and subsequent sloughing, Chemical phlebitis.
Related
- Drug class: All trometamol drugs
- Manufacturer: Pfizer — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Allergic conjunctivitis
- Indication: Drugs for Post-Op Ocular Inflammation
- Indication: Drugs for Post-Op Photophobia